|Day Low/High||246.82 / 250.75|
|52 Wk Low/High||195.50 / 340.34|
Cramer agrees with analysts' bullish calls on Gap and Allergan.
Here are Monday's top research calls, including upgrades for Alaska Air and PulteGroup, a downgrade for Tableau Data and new coverage on Allergan.
Stocks have an up-and-down week as the earnings floodgates open. Portfolio moves include cutting one position.
The company sans CEO Scangos needs to do some type of deal in the coming months.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
- Famed actress launches charitable partnership with Guide Dogs for the Blind and discusses her experience and treatment with RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% -
-- Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily NAMZARIC --
Cramer is a fan of Danaher and says to stick with CBRL Group.
Monday's headlines predicted a gloomy earnings season, Cramer says. What were they thinking?
Stocks kept climbing this week as earnings season got into high gear. We cut one name from the portfolio and rerated a few holdings.
The Israeli pharmaceutical company ought to achieve good terms as fixed-income investors flock to corporate bonds.
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.
At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.
The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.
Continue a repair trade in AGN with a ratio call spread on top of stock already owned.
Here's a technical look at how to trade some of the most active stocks on the market right now.
A look at how we are evaluating today’s market action.
Sequoia Fund has sold its position in Valeant Pharmaceuticals and has added four new positions.
The company once held a 30% stake in Valeant, now owns no Valeant shares.
Endo Pharmaceuticals is most under pressure, analysts say.
Cramer says there are several reasons why the market has risen since the Brexit vote.